Shattuck Labs, Inc. (STTK) | Investment Case

1. Company Snapshot

1.a. Company Description

Shattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States.The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers.It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma.

The company was incorporated in 2016 and is headquartered in Austin, Texas.

Show Full description

1.b. Last Insights on STTK

Here is a 90-word analysis of the positive drivers behind Shattuck Labs' recent performance: Shattuck Labs' corporate update and presentation at the J.P. Morgan Healthcare Conference highlighted its upcoming key milestones in 2025. The company's oral presentation at the 20th Congress of ECCO showcased positive data from its preclinical GLP toxicology study of SL-325, a first-in-class DR3 blocking antibody, demonstrating no evidence of toxicity or residual agonism in non-human primates. This milestone brings the company closer to an IND filing in Q3 2025. Additionally, Shattuck's participation in multiple conferences and presentations has increased visibility and awareness of its novel therapeutics.

1.c. Company Highlights

Last Price	3.1
Change Percentage	4.38%
Open	2.97
Previous Close	2.97
Market Cap ( Millions)	148
Volume	495774
Year High	3.12
Year Low	0.69
M A 50	2.1
M A 200	1.35

FCF Yield	-32.88%
Dividend Yield	0.00%
ROE	-73.82%
Debt / Equity	1.88%
Net Debt / EBIDTA	74.98%
Price To Book	2.4
Price Earnings Ratio	-4.08
Price To FCF	-3.04
Price To sales	4.28
EV / EBITDA	-1.98

2. Transcript Summary

Unfortunately this company is not part of our coverage yet. But as part of your subscription plan you can request it by clicking just below and we'll process.

Request Coverage

3. NewsRoom

Analyst Upgrade Boosts Shattuck On Confidence In Next-Gen Inflammatory Bowel Disease Therapy

Dec -01

Source: benzinga.com

Shattuck Labs to Participate in Upcoming December Investor Conferences

Nov -20

Source: globenewswire.com

Shattuck Labs Reports Third Quarter 2025 Financial Results and Recent Business Highlights

Nov -06

Source: globenewswire.com

Shattuck Labs, Inc. (STTK) Presents at The United European Gastroenterology (UEG) Congress UEG Week 2025 Transcript

Oct -11

Source: seekingalpha.com

What Makes Shattuck Labs, Inc. (STTK) a Strong Momentum Stock: Buy Now?

Oct -08

Source: zacks.com

Shattuck Labs Announces Participation in Upcoming Wedbush Securities Key Opinion Leader (KOL) and Company Panel

Oct -02

Source: globenewswire.com

Should You Buy Shattuck Labs, Inc. (STTK) After Golden Cross?

Sep -19

Source: zacks.com

Shattuck Labs (STTK) Upgraded to Buy: What Does It Mean for the Stock?

Sep -08

Source: zacks.com

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Pharmaceutical

Expected Growth: 10.43%

Shattuck Labs, Inc.'s pharmaceutical segment growth of 10.43% is driven by increasing demand for immunooncology treatments, strategic partnerships, and expansion into new markets. Additionally, the company's focus on developing novel bispecific antibodies and proprietary Agonist Redirected Checkpoint (ARC) technology is contributing to its growth momentum.

7. Detailed Products

SL-1721

SL-1721 is a bispecific antibody that targets PD-1 and SLAMF7, which are both checkpoint receptors that can inhibit the immune system's ability to fight cancer.

SL-279252

SL-279252 is a small molecule inhibitor of the CD47-SIRPα axis, which is a key immune checkpoint pathway that can suppress the immune system's ability to fight cancer.

SL-701

SL-701 is a bispecific antibody that targets PD-1 and LAG-3, which are both checkpoint receptors that can inhibit the immune system's ability to fight cancer.

8. Shattuck Labs, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Shattuck Labs, Inc. has a moderate threat of substitutes due to the presence of alternative treatments and therapies in the market.

Bargaining Power Of Customers

Shattuck Labs, Inc. has a low bargaining power of customers due to the specialized nature of its products and limited customer base.

Bargaining Power Of Suppliers

Shattuck Labs, Inc. has a moderate bargaining power of suppliers due to the availability of multiple suppliers for raw materials and equipment.

Threat Of New Entrants

Shattuck Labs, Inc. has a high threat of new entrants due to the growing demand for biotechnology products and the presence of venture capital funding.

Intensity Of Rivalry

Shattuck Labs, Inc. operates in a highly competitive industry with multiple players, leading to a high intensity of rivalry.

9. SWOT Analysis

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

	Value
Debt Weight	2.82%
Debt Cost	3.95%
Equity Weight	97.18%
Equity Cost	13.87%
WACC	13.59%
Leverage	2.90%

11. Quality Control: Shattuck Labs, Inc. passed 3 out of 9 key points

Strong Liquidity

Low Debt

Strong Interest Coverage

Healthy Cash Flow

Operating Efficiency

Strong Return On Equity

Consistent Revenue Growth

Consistent Operating Cash Flow Growth

Margin Improvement

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Daré Bioscience

A-Score: 4.8/10

Value: 10.0

Growth: 6.9

Quality: 8.6

Yield: 0.0

Momentum: 1.0

Volatility: 2.3

1-Year Total Return ->

Quantum-Si

A-Score: 4.3/10

Value: 7.0

Growth: 4.8

Quality: 4.5

Yield: 0.0

Momentum: 9.0

Volatility: 0.3

1-Year Total Return ->

IGM Biosciences

A-Score: 3.8/10

Value: 9.4

Growth: 7.1

Quality: 4.3

Yield: 0.0

Momentum: 0.0

Volatility: 2.0

1-Year Total Return ->

Shattuck Labs

A-Score: 3.6/10

Value: 7.8

Growth: 1.1

Quality: 3.8

Yield: 0.0

Momentum: 8.5

Volatility: 0.3

1-Year Total Return ->

Avid Bioservices

A-Score: 3.6/10

Value: 4.2

Growth: 4.4

Quality: 1.4

Yield: 0.0

Momentum: 7.5

Volatility: 4.0

1-Year Total Return ->

Precision BioSciences

A-Score: 3.0/10

Value: 6.6

Growth: 5.0

Quality: 3.5

Yield: 0.0

Momentum: 1.5

Volatility: 1.7

1-Year Total Return ->

Peers Metrics

12.e Scoring ^Insights

12.f DCF ^BETA

Parameters

Short Term Growth

21.25%

Short term Time

10.0

Long-Term Growth

2.00%

WACC

13.59%

Shattuck Labs, Inc. - US82024L1035

1. Company Snapshot

1.a. Company Description

1.b. Last Insights on STTK

1.c. Company Highlights

Strong Momentum

Lower Growth

Lower Quality

Earnings Beats

Revenues Beats

Earnings Miss

Medium Volatility

More Volatile

Weak Momentum

Cheaper

2. Transcript Summary

3. NewsRoom

4. Business Breakdown

4.a. Revenues by Country

4.b. Revenues by Segment

5. Expected revenues mid-term growth (10.43%)

6. Segments

Pharmaceutical

Expected Growth: 10.43%

7. Detailed Products

SL-1721

SL-279252

SL-701

8. Shattuck Labs, Inc.'s Porter Forces

Forces Ranking

Threat Of Substitutes

Bargaining Power Of Customers

Bargaining Power Of Suppliers

Threat Of New Entrants

Intensity Of Rivalry

9. SWOT Analysis

Strength

Weaknesses

Opportunities

Threats

10. Capital Structure

10.a. Balance Sheet

10.b. Weighted Average Cost of capital

11. Quality Control: Shattuck Labs, Inc. passed 3 out of 9 key points

12.a Historical Valuation

12.b Price/Earnings Ratio

12.c Margin Valuation

12.d Peers Valuation

Peers Group Analysis

Peers Metrics

12.e Scoring Insights

12.f DCF BETA

Parameters

Short Term Growth

Short term Time

Long-Term Growth

WACC

Target Price

3.1$

Current Price

3.1$

Potential

-0.00%

Expected Cash-Flows

12.e Scoring ^Insights

12.f DCF ^BETA